Patents by Inventor Berge A. Minassian
Berge A. Minassian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240141355Abstract: Provided herein are methods, compounds, and compositions for reducing expression of GYS1 in an individual. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate a glycogen storage disease or disorder in an individual in need.Type: ApplicationFiled: June 8, 2023Publication date: May 2, 2024Inventors: Tamar R. Grossman, Susan M. Freier, Berge Minassian, Saija Ahonen
-
Transgene cassettes, AAV vectors, and AAV viral vectors for expression of human codon-optimized CSTB
Patent number: 11946065Abstract: The present disclosure provides methods and compositions for the treatment of diseases and genetic disorders linked to CSTB loss and/or misfunction. The methods and compositions of the present disclosure include rAAV vectors and rAAV viral vectors comprising transgene nucleic acid molecules encoding CSTB polypeptides.Type: GrantFiled: July 28, 2021Date of Patent: April 2, 2024Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMInventors: Berge A. Minassian, Emrah Gumusgoz -
Patent number: 11713462Abstract: Provided herein are methods, compounds, and compositions for reducing expression of GYS1 in an individual. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate a glycogen storage disease or disorder in an individual in need.Type: GrantFiled: December 23, 2021Date of Patent: August 1, 2023Assignees: Ionis Pharmaceuticals, Inc., The Hospital for Sick ChildrenInventors: Tamar R. Grossman, Susan M. Freier, Berge Minassian, Saija Ahonen
-
Publication number: 20220112502Abstract: Provided herein are methods, compounds, and compositions for reducing expression of GYS1 in an individual. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate a glycogen storage disease or disorder in an individual in need.Type: ApplicationFiled: December 23, 2021Publication date: April 14, 2022Inventors: Tamar R. Grossman, Susan M. Freier, Berge Minassian, Saija Ahonen
-
TRANSGENE CASSETTES, AAV VECTORS, AND AAV VIRAL VECTORS FOR EXPRESSION OF HUMAN CODON-OPTIMIZED CSTB
Publication number: 20220049270Abstract: The present disclosure provides methods and compositions for the treatment of diseases and genetic disorders linked to CSTB loss and/or misfunction. The methods and compositions of the present disclosure include rAAV vectors and rAAV viral vectors comprising transgene nucleic acid molecules encoding CSTB polypeptides.Type: ApplicationFiled: July 28, 2021Publication date: February 17, 2022Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMInventors: Berge A. MINASSIAN, Emrah GUMUSGOZ -
Patent number: 11236339Abstract: Provided herein are methods, compounds, and compositions for reducing expression of GYS1 in an individual. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate a glycogen storage disease or disorder in an individual in need.Type: GrantFiled: June 19, 2017Date of Patent: February 1, 2022Assignees: Ionis Pharmaceuticals, Inc., The Hospital for Sick ChildrenInventors: Tamar R. Grossman, Susan M. Freier, Berge Minassian, Saija Ahonen
-
Patent number: 10954520Abstract: There is a need for delivery platforms with robust capacity that offer the possibility to deliver diverse protein-based therapeutics into specific cells. Described herein is a platform for delivering cargo polypeptides into cells, which is based on a recombinant molecule comprising: a cargo polypeptide, a diphtheria toxin enzymatic fragment (DTA), and a diphtheria toxin translocation fragment (DTB). The platform has been employed to deliver diverse cargo into cells, including those having low or high molecular weights. A hyper-stable cargo polypeptide has been delivered, as well as proteins of therapeutic significance (e.g, MecP2, SMN, FMRP, PNP, alpha-amylase, RRSP, GRA16, and GRA24). The platform is also useful for delivering genome-modifying proteins, such as the CRISPR protein, Cas9.Type: GrantFiled: March 23, 2020Date of Patent: March 23, 2021Assignee: The Hospital for Sick ChildrenInventors: Roman A. Melnyk, Anick Auger, Greg Beilhartz, Berge Minassian, Seiji Sugiman-Marangos
-
Publication number: 20200270693Abstract: The invention is a novel MECP2E1 splice variant and its corresponding polypeptide. The invention also includes methods of using these nucleic acid sequences and proteins in medical diagnosis and treatment of neuropsychiatric disorders or development disorders.Type: ApplicationFiled: March 2, 2020Publication date: August 27, 2020Applicants: The Hospital for Sick Children, Centre for Addiction and Mental HealthInventors: Berge A. Minassian, John B. Vincent
-
Publication number: 20200270695Abstract: The invention is a novel MECP2E1 splice variant and its corresponding polypeptide. The invention also includes methods of using these nucleic acid sequences and proteins in medical diagnosis and treatment of neuropsychiatric disorders or development disorders.Type: ApplicationFiled: March 2, 2020Publication date: August 27, 2020Applicants: The Hospital For Sick Children, Centre for Addiction and Mental HealthInventors: Berge A. Minassian, John B. Vincent
-
Publication number: 20200255483Abstract: There is a need for delivery platforms with robust capacity that offer the possibility to deliver diverse protein-based therapeutics into specific cells. Described herein is a platform for delivering cargo polypeptides into cells, which is based on a recombinant molecule comprising: a cargo polypeptide, a diphtheria toxin enzymatic fragment (DTA), and a diphtheria toxin translocation fragment (DTB). The platform has been employed to deliver diverse cargo into cells, including those having low or high molecular weights. A hyper-stable cargo polypeptide has been delivered, as well as proteins of therapeutic significance (e.g, MecP2, SMN, FMRP, PNP, alpha-amylase, RRSP, GRA16, and GRA24). The platform is also useful for delivering genome-modifying proteins, such as the CRISPR protein, Cas9.Type: ApplicationFiled: March 23, 2020Publication date: August 13, 2020Applicant: The Hospital for Sick ChildrenInventors: Roman A. MELNYK, Anick AUGER, Greg BEILHARTZ, Berge MINASSIAN, Seiji SUGIMAN-MARANGOS
-
Patent number: 10597663Abstract: There is a need for delivery platforms with robust capacity that offer the possibility to deliver diverse protein-based therapeutics into specific cells. Described herein is a platform for delivering cargo polypeptides into cells, which is based on a recombinant molecule comprising: a cargo polypeptide, a diphtheria toxin enzymatic fragment (DTA), and a diphtheria toxin translocation fragment (DTB). The platform has been employed to deliver diverse cargo into cells, including those having low or high molecular weights. A hyper-stable cargo polypeptide has been delivered, as well as proteins of therapeutic significance (e.g, MecP2, SMN, FMRP, PNP, alpha-amylase, and RRSP). The platform is also useful for delivering genome-modifying proteins, such as the CRISPR protein, Cas9. Associated nucleic acids, pharmaceutical compositions, methods, uses, and kits are also described, including those of therapeutic significance aimed at treating diseases or disorders caused by enzyme or protein deficiency.Type: GrantFiled: November 30, 2017Date of Patent: March 24, 2020Assignee: THE HOSPITAL FOR SICK CHILDRENInventors: Roman A. Melnyk, Anick Auger, Greg Beilhartz, Berge Minassian, Seiji Sugiman-Marangos
-
Patent number: 10577658Abstract: The invention is a novel MECP2E1 splice variant and its corresponding polypeptide. The invention also includes methods of using these nucleic acid sequences and proteins in medical diagnosis and treatment of neuropsychiatric disorders or development disorders.Type: GrantFiled: March 7, 2018Date of Patent: March 3, 2020Assignees: The Hospital for Sick Children, Centre for Addiction and Mental HealthInventors: Berge A. Minassian, John B. Vincent
-
Patent number: 10577657Abstract: The invention is a novel MECP2E1 splice variant and its corresponding polypeptide. The invention also includes methods of using these nucleic acid sequences and proteins in medical diagnosis and treatment of neuropsychiatric disorders or development disorders.Type: GrantFiled: March 7, 2018Date of Patent: March 3, 2020Assignees: The Hospital For Sick Children, Centre for Addiction and Mental HealthInventors: Berge A. Minassian, John B. Vincent
-
Publication number: 20190194666Abstract: Provided herein are methods, compounds, and compositions for reducing expression of GYS1 in an individual. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate a glycogen storage disease or disorder in an individual in need.Type: ApplicationFiled: June 19, 2017Publication date: June 27, 2019Applicants: Ionis Pharmaceuticals, Inc., The Hospital for Sick ChlidrenInventors: Tamar R. Grossman, Susan M. Freier, Berge Minassian, Saija Ahonen
-
Publication number: 20180265926Abstract: The invention is a novel MECP2E1 splice variant and its corresponding polypeptide. The invention also includes methods of using these nucleic acid sequences and proteins in medical diagnosis and treatment of neuropsychiatric disorders or development disorders.Type: ApplicationFiled: March 7, 2018Publication date: September 20, 2018Applicants: The Hospital For Sick Children, Centre for Addiction and Mental HealthInventors: Berge A. Minassian, John B. Vincent
-
Publication number: 20180265927Abstract: The invention is a novel MECP2E1 splice variant and its corresponding polypeptide. The invention also includes methods of using these nucleic acid sequences and proteins in medical diagnosis and treatment of neuropsychiatric disorders or development disorders.Type: ApplicationFiled: March 7, 2018Publication date: September 20, 2018Applicants: The Hospital for Sick Children, Centre for Addiction and Mental HealthInventors: Berge A. Minassian, John B. Vincent
-
Publication number: 20180080033Abstract: There is a need for delivery platforms with robust capacity that offer the possibility to deliver diverse protein-based therapeutics into specific cells. Described herein is a platform for delivering cargo polypeptides into cells, which is based on a recombinant molecule comprising: a cargo polypeptide, a diphtheria toxin enzymatic fragment (DTA), and a diphtheria toxin translocation fragment (DTB). The platform has been employed to deliver diverse cargo into cells, including those having low or high molecular weights. A hyper-stable cargo polypeptide has been delivered, as well as proteins of therapeutic significance (e.g, MecP2, SMN, FMRP, PNP, alpha-amylase, and RRSP). The platform is also useful for delivering genome-modifying proteins, such as the CRISPR protein, Cas9. Associated nucleic acids, pharmaceutical compositions, methods, uses, and kits are also described, including those of therapeutic significance aimed at treating diseases or disorders caused by enzyme or protein deficiency.Type: ApplicationFiled: November 30, 2017Publication date: March 22, 2018Inventors: Roman A. MELNYK, Anick AUGER, Greg BEILHARTZ, Berge MINASSIAN, Seiji SUGIMAN-MARANGOS
-
Publication number: 20170152564Abstract: The invention is a novel MECP2E1 splice variant and its corresponding polypeptide. The invention also includes methods of using these nucleic acid sequences and proteins in medical diagnosis and treatment of neuropsychiatric disorders or development disorders.Type: ApplicationFiled: February 9, 2017Publication date: June 1, 2017Applicants: The Hospital for Sick Children, Centre for Addiction and Metal HealthInventors: Berge A. Minassian, John B. Vincent
-
Publication number: 20170137887Abstract: The invention is a novel MECP2E1 splice variant and its corresponding polypeptide. The invention also includes methods of using these nucleic acid sequences and proteins in medical diagnosis and treatment of neuropsychiatric disorders or development disorders.Type: ApplicationFiled: January 31, 2017Publication date: May 18, 2017Applicants: The Hospital for Sick Children, Centre for Addiction and Mental HealthInventors: Berge A. Minassian, John B. Vincent
-
Patent number: 9605314Abstract: The invention is a novel MECP2E1 splice variant and its corresponding polypeptide. The invention also includes methods of using these nucleic acid sequences and proteins in medical diagnosis and treatment of neuropsychiatric disorders or development disorders.Type: GrantFiled: December 9, 2013Date of Patent: March 28, 2017Assignees: The Hospital for Sick Children, Centre for Addiction and Mental HealthInventors: Berge A. Minassian, John B. Vincent